Miami AI Surgical Error Lawyer

AI in the Operating Room: Surgical Device Errors, Hospital Negligence, and Patient Safety in Florida

Artificial intelligence is no longer “future medicine.” It is already inside the tools used to guide surgeons, label anatomy on imaging, and interpret physiologic signals in real time. That shift can create real benefits—but it also creates new failure modes that look nothing like a “traditional” surgical mistake.

A recent Reuters investigation highlights this exact problem: when AI features were added to certain surgical navigation and clinical tools, reports to the FDA increased and injuries were alleged, including serious events like CSF leaks, skull-base punctures, and strokes in connection with sinus surgery navigation guidance.

For Florida patients and families, our Miami, FL AI surgical error lawyer knows that the question is practical—not philosophical:

When an AI-enabled medical device is used during surgery or hospital care, what can go wrong, how is it tracked, and what evidence matters if a patient is injured?

This page explains (1) what “AI in the operating room” actually means, (2) how AI-enabled surgical tools can fail, (3) what FDA adverse-event reports can and cannot prove, and (4) how hospitals and manufacturers are supposed to manage risk across the device’s lifecycle.

If you are in need of assistance, contact Needle & Ellenberg, P.A. today.

What “AI in the operating room” really means

Most people imagine a robot autonomously performing surgery. That is not the typical use case.

In real hospitals and ambulatory surgery centers, “AI in the OR” is usually software embedded into devices clinicians already use, such as:

• Surgical navigation systems (guidance about instrument position relative to anatomy)
• Imaging tools that label/segment anatomy or enhance images (e.g., ultrasound labeling)
• Monitoring and detection algorithms that classify rhythms or physiologic signals (e.g., arrhythmia detection)

The safety issue is straightforward: if software changes what the clinician believes is true—where the instrument tip is, what structure is on the screen, or what rhythm is occurring—a software error can become physical harm.

The Reuters investigation: why it matters to patients

Reuters reviewed FDA adverse-event reports and litigation claims to describe how AI is entering clinical care—and how post-market reporting is often where hazards first appear.

The investigation’s headline lesson: after AI features were added to a surgical navigation system used in sinus procedures, FDA received substantially more reports, and at least 10 reported injuries were tied to alleged “wrong location” guidance during surgeries between late 2021 and November 2025.

The specific details matter because they map to a classic patient-safety pattern:

• A tool is marketed as an improvement (“smarter,” “more accurate,” “AI-enhanced”).
• Real-world use reveals conditions the system struggles with (anatomic variants, registration issues, workflow variability).
• Reports rise—often before definitive conclusions can be drawn.
• Manufacturers and clinicians may dispute causation, and patients can be left with catastrophic injury without a clear explanation.

Reuters also emphasizes a key constraint: FDA reports can be incomplete and are not designed to determine causation by themselves.

Case example: AI-added surgical navigation and reported injuries

Reuters’ anchor example involves the TruDi Navigation System, originally distributed by Acclarent, which was later acquired by Integra LifeSciences (per Reuters’ reporting).

According to Reuters:

• Before AI was added (device already on market ~3 years), the FDA had received reports of malfunctions and one injury report.
• After AI was added (announced in 2021), the FDA received at least 100 reports of malfunctions and adverse events.
• At least 10 injuries were reported from late 2021 through November 2025, including allegations of instrument-location misinformation with outcomes such as CSF leak, skull-base puncture, and strokes after major artery injury.

Two stroke victims filed lawsuits in Texas alleging AI contributed to their injuries; the device owner disputed any causal link and emphasized that reports only show a system was in use when an adverse event occurred.

Why this matters for Florida patients: even when causation is contested, these events illustrate what a modern surgical injury case can look like—where the dispute is not merely “surgeon error,” but whether device performance, software changes, training, warnings, or hospital governance played a role.

How AI-enabled surgical devices fail (real-world failure modes)

AI device failures often look “plausible” to clinicians in the moment. That’s what makes them dangerous.

A. Registration and alignment errors (navigation “drift”)

Navigation guidance depends on aligning images and tracking hardware to the patient’s anatomy. Small alignment errors can become clinically meaningful—especially in skull base/sinus work where millimeters matter.

If an AI module changes how registration is performed (or makes the system more sensitive to certain imaging conditions), the tool can appear functional but be wrong.

B. “Wrong anatomy” labeling or segmentation

AI may label or segment structures (e.g., boundaries, critical anatomy). If the model misidentifies structures—particularly with anatomic variants, inflammation, scarring, or unusual imaging parameters—the output can be confidently wrong.

Reuters references reporting about AI tools in other clinical contexts (e.g., ultrasound labeling concerns), reflecting this general failure mode.

C. Human factors: automation bias and false confidence

A major risk is not just error—it’s overreliance.

If a system looks precise (clean UI, stable guidance markers), clinicians may subconsciously trust it more than they should. Patient safety organizations have repeatedly warned that AI output can be misleading and that robust guardrails are needed.

D. Software updates and lifecycle risk

Unlike a physical instrument, AI is software. Software changes—new versions, tuning, “performance improvements”—can shift accuracy across patient types and surgical contexts. The FDA has been pushing a total product lifecycle (TPLC) risk-management approach for AI-enabled device software functions.

E. Edge cases are common in real surgery

AI can perform well in “typical” cases and fail in the exact cases that are hardest: revision surgeries, severe disease, unusual anatomy, pediatric cases, or compromised imaging quality.

FDA adverse-event reports (MAUDE): what they mean and their limits

When a serious device concern arises, one of the first public signals is often the FDA’s MAUDE database (Manufacturer and User Facility Device Experience).

What MAUDE is

MAUDE contains medical device reports (MDRs) of adverse events submitted by manufacturers, importers, and user facilities, and sometimes by clinicians or consumers.

What MAUDE is not

MAUDE reports:

• Can be incomplete or inaccurate.
• Often lack key clinical details.
• Are not designed to establish that a device caused the injury.

Peer-reviewed commentary also emphasizes known limitations of MAUDE, including reliance on passive reporting and incomplete clinical context.

Practical takeaway: a cluster of reports is not “proof,” but it can be a meaningful safety signal—especially when the reported malfunction mode matches the injury mechanism (e.g., “instrument location wrong” + vascular injury).

FDA oversight: why devices can reach patients without “big trials”

Many patients assume all medical devices go through large clinical trials. That is not always how device regulation works—especially for certain device categories.

The FDA has issued guidance framing how it evaluates AI-enabled device software functions and what manufacturers should include in marketing submissions, emphasizing a TPLC risk-management approach.

The key point for patients: depending on the regulatory pathway, a device can be cleared or authorized without the kind of large, prospective randomized trial people associate with drugs. That reality increases the importance of:

• Manufacturer validation and transparency
• Hospital governance and training
• Post-market surveillance signals (like MAUDE)
• Recall responsiveness and corrective actions

Recalls and validation gaps: what research is showing

Independent research is increasingly examining whether AI-enabled devices are reaching patients with limited clinical validation and how recalls occur.

A JAMA Health Forum study (“Early Recalls and Clinical Validation Gaps in Artificial Intelligence–Enabled Medical Devices”) evaluates the association between clinical validation and recall patterns among FDA-cleared AI-enabled devices.

Separately, a 2025 npj Digital Medicine paper reviewed 1,016 FDA authorizations of AI/ML-enabled medical devices and built a taxonomy describing how AI is being used across devices—useful context for scale and complexity.

Why this matters in litigation and patient safety reviews: recalls and validation gaps can inform whether a device’s real-world performance risk was foreseeable, how promptly issues were corrected, and what warnings/training were provided.

Why patient safety groups are flagging AI as a top technology hazard

ECRI, a prominent patient-safety organization, ranked AI-enabled health technology risks as the #1 health technology hazard for 2025 and warned that AI can generate false or misleading results without proper oversight and guardrails.

For hospitals, this reinforces an operational truth: “AI-enabled” does not mean “safe-by-default.” It means new risk surfaces that require governance.

Hospital responsibilities when using AI-enabled devices in surgery

In a safety-first system, hospitals and surgery centers should treat AI-enabled devices like high-risk clinical tools, not plug-and-play software.

Key responsibilities include:

Credentialing and training

• Training on the device and on known failure modes
• Documentation of competency and supervised use during early adoption

Version control and change management

• Tracking software versions used in the facility
• Controlled rollout of updates
• Documentation of vendor advisories and training updates

Incident monitoring beyond “reportable harm”

• Tracking near-misses and anomalies
• Escalation pathways to risk management and biomedical engineering
• Prompt reporting and investigation when guidance appears inaccurate

Informed consent transparency (practical reality)

Even if not always legally mandated in a uniform way, transparency is risk-reducing when a tool materially affects technique or risk profile:

• Was an AI-enabled navigation tool used?
• What is the fallback plan if guidance conflicts with anatomy or imaging?
• Will the device name/version be recorded in the operative documentation?

Red flags for patients and families

Consider these red flags in any hospital or surgery setting where advanced guidance tools are used:

• The team cannot explain what the system does in plain language.
• No one can answer whether the system has been recently updated.
• There is no clear backup plan if guidance appears inconsistent.
• The record is vague about device name/version used.
• Complications occur that match known navigation/instrument-position failure patterns (e.g., unexpected vascular injury, skull-base injury, CSF leak in ENT/skull-base cases).

What to preserve when an AI-enabled device may be involved

If a patient is injured and an AI-enabled device may have played a role, the evidence is not only medical charts.

You typically want to preserve:

Clinical records

• Pre-op imaging, operative note, anesthesia record
• Nursing record, PACU record, ICU record
• Post-op imaging and complication documentation

Device and software records

• Device name/model and serial number
• Software version and configuration
• Calibration/registration logs (when available)
• Alerts shown to users
• Maintenance and service records
• Vendor advisories/field notices

Hospital governance records

• Training materials and credentialing/competency records
• Policies for device updates and monitoring
• Incident reports and internal investigations

Why this matters

FDA adverse-event reports may not contain enough detail to establish what happened in a specific case. Both the FDA and Reuters emphasize limitations and non-causation of adverse-event reports standing alone.

Frequently Asked Questions (FAQ)

Is an FDA adverse-event report proof a device caused an injury?

No. FDA reporting systems are important for surveillance, but reports can be incomplete and are not intended to determine causation.

If AI is involved, does that mean the surgeon did nothing wrong?

Not necessarily. Many cases involve multiple contributors: surgical judgment, hospital training/governance, and device performance. The key question is what actually happened and what should have been done to prevent it.

Can a device be “cleared” even if it later shows safety problems?

Yes. That is one reason post-market surveillance and recalls exist—and why independent research is studying early recall patterns and validation gaps for AI-enabled devices.

Why is AI harder to regulate than traditional devices?

Because software can change quickly (updates, retraining, tuning), and real-world performance can vary across environments and patient types. FDA guidance emphasizes lifecycle risk management for AI-enabled device software functions.

Is AI considered a major patient safety concern right now?

Yes. ECRI ranked AI-related health technology risk as the top hazard for 2025 and warned about misleading outputs without proper guardrails.

If you need help after a suspected device-related injury (Florida)

If you believe a surgical complication involved more than “routine risk”—especially where advanced guidance systems, navigation tools, or AI-enabled imaging were in play—your first step is evidence preservation. Modern cases often turn on device/software specifics that are not obvious in the standard chart.

Needle & Ellenberg’s hospital negligence and catastrophic injury work focuses on preventable failures in systems of care—where technology, training, and governance can matter as much as the hands in the operating room.